Cover Image
Market Research Report
Product code 
980034

Advanced Glycation End Products Market, by Type (Non-fluorescent AGEs and Fluorescent AGEs ), by Application, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published: | Coherent Market Insights | 105 Pages | Delivery time: 2-3 business days

Price

Back to Top
Advanced Glycation End Products Market, by Type (Non-fluorescent AGEs and Fluorescent AGEs ), by Application, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
Published: December 28, 2020
Coherent Market Insights
Content info: 105 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

Title:
Advanced Glycation End Products Market, by Type (Non-fluorescent AGEs (Carboxymethyl-lysine (CML), Carboxyethyl-lysine (CEL), and Pyrraline) and Fluorescent AGEs (Pentosidine and Methylglyoxal-lysine dimer (MOLD))), by Application (Diabetic Complications, Cancer, Bone Diseases, Neurodegenerative Diseases, and Others), by End User (Hospitals, Specialty Clinics, and Homecare Settings), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Advanced glycation end products (AGEs), also known as glycotoxins or atherogenic molecules, are the diverse group of highly oxidant compounds. AGEs are formed through a non-enzymatic reaction between reducing sugars and free amino groups of proteins, lipids, or nucleic acids. This reaction is also known as the Maillard or browning reaction. Advanced glycation end products (AGEs) are used to treat pathological conditions such as diabetes mellitus (DM), cardiovascular disease, Alzheimer's disease, cancer, and natural aging. Increasing prevalence of cardiovascular diseases (CVD) is expected to drive growth of the advanced glycation end products market. According to the American Heart Association, 2016, cardiovascular diseases account for 17.3 million deaths every year, globally, where an estimated 23.3 million people are expected to die from CVD by 2030. Such rising prevalence of chronic diseases is expected to drive the advanced glycation end products market growth over the forecast period.

Market Dynamics

Market players are focusing on research and development of advanced glycation end products in diabetic complications as advanced glycation end products (AGEs) are key factor in the development of metabolic memory in diabetic complications, which is expected to drive growth of the global advanced glycation end products market over the forecast period. According to the International Diabetes Federation (IDF), in 2017, the estimated number of 18 to 99 year old diabetic patients was around 425 million globally.

Key features of the study:

  • This report provides in-depth analysis of the global advanced glycation end products market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global advanced glycation end products market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Merck KGaA, Diagnoptics Technologies B.V., Cell Biolabs, Inc., Shanghai Korain Biotech Co., Ltd, Scent-Sations, Inc., Z.I. de la Nau, and KOKEN CO., LTD. among others
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global advanced glycation end products market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global advanced glycation end products market

Detailed Segmentation:

  • Global Advanced Glycation End Products Market, By Type:
    • Non-fluorescent AGEs
      • Carboxymethyl-lysine (CML)
      • Carboxyethyl-lysine (CEL)
      • Pyrraline
    • Fluorescent AGEs
      • Pentosidine
      • Methylglyoxal-lysine dimer (MOLD)
  • Global Advanced Glycation End Products Market, By Application:
    • Diabetic Complications
    • Cancer
    • Bone Diseases
    • Neurodegenerative Diseases
    • Others
  • Global Advanced Glycation End Products Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Homecare Settings
  • Global Advanced Glycation End Products Market, By Region:
    • North America
      • By Type:
      • Non-fluorescent AGEs
      • Carboxymethyl-lysine (CML)
      • Carboxyethyl-lysine (CEL)
      • Pyrraline
      • Fluorescent AGEs
      • Pentosidine
      • Methylglyoxal-lysine dimer (MOLD)
      • By Application
      • Diabetic Complications
      • Cancer
      • Bone Diseases
      • Neurodegenerative Diseases
      • Others
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Homecare Settings
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Type:
      • Non-fluorescent AGEs
      • Carboxymethyl-lysine (CML)
      • Carboxyethyl-lysine (CEL)
      • Pyrraline
      • Fluorescent AGEs
      • Pentosidine
      • Methylglyoxal-lysine dimer (MOLD)
      • By Application
      • Diabetic Complications
      • Cancer
      • Bone Diseases
      • Neurodegenerative Diseases
      • Others
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Homecare Settings
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Type:
      • Non-fluorescent AGEs
      • Carboxymethyl-lysine (CML)
      • Carboxyethyl-lysine (CEL)
      • Pyrraline
      • Fluorescent AGEs
      • Pentosidine
      • Methylglyoxal-lysine dimer (MOLD)
      • By Application
      • Diabetic Complications
      • Cancer
      • Bone Diseases
      • Neurodegenerative Diseases
      • Others
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Homecare Settings
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Type:
      • Non-fluorescent AGEs
      • Carboxymethyl-lysine (CML)
      • Carboxyethyl-lysine (CEL)
      • Pyrraline
      • Fluorescent AGEs
      • Pentosidine
      • Methylglyoxal-lysine dimer (MOLD)
      • By Application
      • Diabetic Complications
      • Cancer
      • Bone Diseases
      • Neurodegenerative Diseases
      • Others
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Homecare Settings
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Type:
      • Non-fluorescent AGEs
      • Carboxymethyl-lysine (CML)
      • Carboxyethyl-lysine (CEL)
      • Pyrraline
      • Fluorescent AGEs
      • Pentosidine
      • Methylglyoxal-lysine dimer (MOLD)
      • By Application
      • Diabetic Complications
      • Cancer
      • Bone Diseases
      • Neurodegenerative Diseases
      • Others
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Homecare Settings
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Homecare Settings
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Type:
      • Non-fluorescent AGEs
      • Carboxymethyl-lysine (CML)
      • Carboxyethyl-lysine (CEL)
      • Pyrraline
      • Fluorescent AGEs
      • Pentosidine
      • Methylglyoxal-lysine dimer (MOLD)
      • By Application
      • Diabetic Complications
      • Cancer
      • Bone Diseases
      • Neurodegenerative Diseases
      • Others
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Homecare Settings
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Merck KGaA*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Diagnoptics Technologies B.V
    • Cell Biolabs, Inc.
    • Shanghai Korain Biotech Co., Ltd
    • Scent-Sations, Inc.
    • Z.I. de la Nau
    • KOKEN CO., LTD.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Type
    • Market Snippet, By Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Key Developments
  • PEST Analysis

4. Global Advanced Glycation End Products Market - Impact of Coronavirus (COVID-19) Pandemic

  • Impact assessment
  • Pre COVID-19 Market Scenario
  • Post COVID-19 Market Scenario
  • Government measures to combat COVID-19

5. Global Advanced Glycation End Products Market, By Type, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Non-fluorescent AGEs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Carboxymethyl-lysine (CML)
    • Carboxyethyl-lysine (CEL)
    • Pyrraline
  • Fluorescent AGEs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
    • Pentosidine
    • Methylglyoxal-lysine dimer (MOLD)

6. Global Advanced Glycation End Products Market, By Application, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Diabetic Complications
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Bone Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Neurodegenerative Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

7. Global Advanced Glycation End Products Market, By End User, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Home Care Settings
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

8. Global Advanced Glycation End Products Market, By Region, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2027
  • North America
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Application, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • Merck KGaA
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Diagnoptics Technologies B.V.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Cell Biolabs, Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Shanghai Korain Biotech Co., Ltd
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Scent-Sations, Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Z.I. de la Nau
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • KOKEN CO., LTD.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact